ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1893

Relationship Between Vitamin D Levels and Disease Activity in Patients with Systemic Sclerosis

Julia Romero1, Amalia Schiel2, Mariana Landa2, María Luisa Díaz3, María Eugenia Lara1, Mariano Rivero4, Marina Khoury5, Mirtha Alonso2 and Juan Carlos Barreira1, 1Rheumatology Service, British Hospital, Buenos Aires, Argentina, 2Central Laboratory, British Hospital, Buenos Aires, Argentina, 3Nuclear Medicine, British Hospital, Buenos Aires, Argentina, 4Rheumatolgy Service, British Hospital, Buenos Aires, Argentina, 5Teaching and Research, British Hospital, Buenos Aires, Argentina

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Vitamin D and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Low Vitamin D (VD) levels have been observed in several autoimmune diseases, including systemic sclerosis (SSc). Some studies have shown the importance of VD in SSc, but its significance has not yet been determined. We aim to evaluate differences in serum levels of VD in SSc patients compared to a control group, and to correlate such levels with disease activity, clinical and laboratory features.

Methods: We included patients diagnosed with SSc according to ACR 1980 criteria and subtypes according to Le Roy, who consecutively attended the Rheumatology Service in spring and summer during 2 years. Patients with overlapping syndromes, diseases or drugs that interfered with VD serum level 6 months prior to study entry were excluded. A control group of 58 blood donors without autoimmune disease and negative autoantibodies was matched by sex and age. Determination of 25(OH)D3 was performed through radioimmunoassay-chemiluminescence assay. Levels between 20 and 29.9ng/ml were classified as VD insufficiency while concentrations lower than 20ng/ml as deficiency. For the SSc group, demographic and clinical data were collected, and mRSS (modified Rodnan Skin Score), scleroderma health assessment questionnaire (S-HAQ), EUSTAR Disease Activity Score and Medsger Severity Score were performed. Statistical Analysis: Numerical variables were compared by Student’s t test or Mann-Whitney test and categorical variables by x2 test. A value of p<0.05 was considered significant.

Results: The SSc group included 58 patients; median age of 57 years. The mean value of VD was 19.9±8.7ng/ml in the SSc group, and 29.6±8.6ng/ml in the control group (P<0.001). A total of 29 patients (50%) in the SSc group had deficiency, 20 (34.5%) had insufficiency and 9 (15.5%) presented normal levels. In the control group, 6 (10.3%) presented deficiency, 27 (46.6%) insufficiency and 25 (43.1%) normal VD levels. SSc group patients presented a statistically significant higher frequency of deficiency (p≤0.001) but not of insufficiency (p=0.607). Out of the 22 patients (38%) with diffuse SSc, 17 (77%) presented deficiency, 4 (18%) insufficiency and 1 (5%) normal VD levels. Among the 36 patients (62%) with limited disease, 12 (33%) had deficiency, 16 (44%) insufficiency and 8 (23%) normal levels. The group of diffuse SSc presented a significantly higher frequency of hypovitaminosis D (VD<30ng/ml)(p=0.005). Patients with suboptimal levels showed higher Rodnan Score, S-HAQ, EUSTAR Disease Activity Score (all with p≤0.001) and Medsger Score (p=0.002) and late SD pattern (p=0.049). All presented normal calcemia, calciuria and parathormone. A subgroup of 16 patients (28%) received low doses of steroids (prednisone or equivalent ≤10mg/d) with no significant difference in VD level compared to those who did not receive it.

Conclusion: Hypovitaminosis D was found in more than 80% of SSc patients with a significant difference compared to healthy controls. They presented more frequently the diffuse form, higher cutaneous involvement, more severe and active disease and higher levels of disability.


Disclosure: J. Romero, None; A. Schiel, None; M. Landa, None; M. L. Díaz, None; M. E. Lara, None; M. Rivero, None; M. Khoury, None; M. Alonso, None; J. C. Barreira, None.

To cite this abstract in AMA style:

Romero J, Schiel A, Landa M, Díaz ML, Lara ME, Rivero M, Khoury M, Alonso M, Barreira JC. Relationship Between Vitamin D Levels and Disease Activity in Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/relationship-between-vitamin-d-levels-and-disease-activity-in-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/relationship-between-vitamin-d-levels-and-disease-activity-in-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology